Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India

• Main Authors: Nithin Sashidharan, Smita Shenoy, Meena Kumari Kamal Kishore, Harish Thanusubramanian
• Format: Article
• Language: English
• Published: JCDR Research and Publications Private Limited 2015-05-01
• Series: Journal of Clinical and Diagnostic Research
• Subjects: bortezomib; melphalan; neutropenia; thrombocytopenia
• Online Access: https://jcdr.net/articles/PDF/5895/11798_CE[Ra_Ash]_F(P)_PF1(PAK)_PFA(AK)_PF2(PAG).pdf
• ISSN: 2249-782X; 0973-709X

Background: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario Aim: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomidedexamethasone in the treatment of newly diagnosed cases of multiple myeloma. Settings and Design: Observational Study conducted in tertiary care centre. Materials and Methods: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. Statistical Analysis: Primarily Descriptive. Results: There was no significant difference between thal/ dex and len/dex treatment groups with respect to efficacy and safety in our study. Conclusion: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.